Update on Medical Abortion: Expanding Safe and Equitable, Patient-Centered Care
详细信息    查看全文
  • 作者：Natalie S. Whaley ; Sarah J. Betstadt
  • 关键词：Unsafe abortion ; Medical abortion ; Mifepristone ; Misoprostol ; Task ; shifting
  • 刊名：Current Obstetrics and Gynecology Reports
  • 出版年：2016
  • 出版时间：March 2016
  • 年：2016
  • 卷：5
  • 期：1
  • 页码：48-54
  • 全文大小：281 KB
  • 参考文献：1.Gerdts C, Tuncalp O, Johnston H, Ganatra B. Measuring abortion-related mortality: challenges and opportunities. Reprod Health. 2015;12:87.PubMedCentral CrossRef PubMed
    2.World Health Organization. Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008. 6th ed. Geneva: World Health Organization; 2008.
    3.•
Singh S, Maddow-Zimet I. Facility-based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries. BJOG, 2015. National estimates from 26 countries—including published studies and unpublished data—were used to estimate that 7 million women in the developing world were treated for complications from unsafe abortion in 2012.
4.Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, et al. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9947):980–1004.PubMedCentral CrossRef PubMed
5.World Health Organization. Safe abortion: technical and policy guidance for health systems: legal and policy considerations. Geneva: World Health Organization; 2015.
6.Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004;103(4):729–37.CrossRef PubMed
7.Institute G. Facts on induced abortion worldwide. 2012.
8.Vlassoff M, Walker D, Shearer J, Newlands D, Singh S. Estimates of health care system costs of unsafe abortion in Africa and Latin America. Int Perspect Sex Reprod Health. 2009;35(3):114–21.CrossRef PubMed
9.World Health Organization. The prevention and management of unsafe abortion: report of a technical working group in Geneva, 12–15 April 1992. Geneva: World Health Organization; 1992.
10.Ganatra B, Tuncalp O, Johnston HB, Johnson Jr BR, Gulmezoglu AM, Temmerman M. From concept to measurement: operationalizing WHO’s definition of unsafe abortion. Bull World Health Organ. 2014;92(3):155.PubMedCentral CrossRef PubMed
11.World Health Organization. Safe abortion: technical and policy guidance for health systems. 2nd ed. Geneva: World Health Organization; 2012.
12.Haider S, Stoffel C, Donenberg G, Geller S. Reproductive health disparities: a focus on family planning and prevention among minority women and adolescents. Glob Adv Health Med. 2013;2(5):94–9.PubMedCentral CrossRef PubMed
13.Jones RK, Kavanaugh ML. Changes in abortion rates between 2000 and 2008 and lifetime incidence of abortion. Obstet Gynecol. 2011;117(6):1358–66.CrossRef PubMed
14.Hutcheon JA, Bodnar LM, Simhan HN. Medicaid pregnancy termination funding and racial disparities in congenital anomaly-related infant deaths. Obstet Gynecol. 2015;125(1):163–9.CrossRef PubMed
15.Grossman D, White K, Hopkins K, Potter JE. The public health threat of anti-abortion legislation. Contraception. 2014;89(2):73–4.PubMedCentral CrossRef PubMed
16.Grossman D, Holt K, Peña M, et al. Self-induction of abortion among women in the United States. Reprod Health Matters. 2010;18(36):136–46.CrossRef PubMed
17.Grimes DA, Benson J, Singh S, et al. Unsafe abortion: the preventable pandemic. Lancet. 2006;368(9550):1908–19.CrossRef PubMed
18.Lim LM, Singh K. Termination of pregnancy and unsafe abortion. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):859–69.CrossRef PubMed
19.Snow RC, Laski L, Mutumba M. Sexual and reproductive health: progress and outstanding needs. Glob Publ Health. 2015;10(2):149–73.CrossRef
20.Chen MJ, Creinin MD. Mifepristone with buccal misoprostol for medical abortion: a systematic review. Obstet Gynecol. 2015;126(1):12–21.CrossRef PubMed
21.Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012;120(5):1070–6.PubMed
22.Bracken H, Dabash R, Tsertsvadze G, et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective comparative open-label trial. Contraception. 2014;89(3):181–6.CrossRef PubMed
23.Sanhueza Smith P, Pena M, Dzuba IG, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reprod Health Matters. 2015;22(44 Suppl 1):75–82.CrossRef PubMed
24.Abbas D, Chong E, Raymond EG. Outpatient medical abortion is safe and effective through 70 days gestation. Contraception. 2015;92(3):197–9.CrossRef PubMed
25.Ireland Ld GM, Chen Ay. Medical compared with surgical abortion for effective pregnancy termination in the first trimester. Am J Obstet Gynecol. 2015;126:1.
26.Blum J, Raghavan S, Dabash R, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012;118(2):166–71.CrossRef PubMed
27.Sheldon GF, Ricketts TC, Charles A, King J, Fraher EP, Meyer A. The global health workforce shortage: role of surgeons and other providers. Adv Surg. 2008;42:63–85.CrossRef PubMed
28.Anyangwe SC, Mtonga C. Inequities in the global health workforce: the greatest impediment to health in Sub-Saharan Africa. Int J Environ Res Publ Health. 2007;4(2):93–100.CrossRef
29.World Health Organization. Optimizing health worker roles to improve access to key maternal and newborn health interventions through task shifting. Geneva: World Health Organization; 2012.
30.Committee on Health Care for Underserved Women. ACOG Committee Opinion No. 613: increasing access to abortion. Obstet Gynecol. 2014;124(5):1060–5.CrossRef
31.••
World Health Organization. Health workers roles in providing safe abortion care and post abortion contraception. Geneva: World Health Organization; 2015. The WHO Guidelines provide evidence-based recommendations on how task-shifting in abortion care can be implemented to improve disparities in access to care in low and high-resource settings.
32.Ganatra B. Health worker roles in safe abortion care and post-abortion contraception. Lancet Glob Health. 2015;3(9):e512–3.CrossRef PubMed
33.••
Barnard S, Kim C, Park MH, Ngo TD. Doctors or mid-level providers for abortion. Cochrane Database Syst Rev. 2015;7:CD011242. This meta-analysis evaluated eight studies with over 22,000 participants to compare the safety and effectiveness of abortion provision by physicians compared to advanced level practitioners (nurse practitioners or nurse midwives) in a range of settings found no difference in the risks of medical abortion failure or complications after first trimester aspiration abortion. PubMed
34.Kopp Kallner H, Gomperts R, Salomonsson E, Johansson M, Marions L, Gemzell-Danielsson K. The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG. 2015;122(4):510–7.CrossRef PubMed
35.Guttmacher Institute. State policies in brief: Medication abortion (2015). Accessed: http://​www.​guttmacher.​org/​statecenter/​spibs/​spib_​MA.​pdf
36.Swica Y, Chong E, Middleton T, et al. Acceptability of home use of mifepristone for medical abortion. Contraception. 2013;88(1):122–7.CrossRef PubMed
37.•
Chong E, Frye LJ, Castle J, Dean G, Kuehl L, Winikoff B. A prospective, non-randomized study of home-use of mifepristone for medical abortion in the U.S. Contraception. 2015. Prospective, non-randomized, open label study in the U.S. enrolled 400 women with pregnancies up to 63 days undergoing medical abortion and found home administration of mifepristone was highly acceptable to women, allowed for flexibility and decreased time missed from work.
38.Gold M, Chong E. If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion. Contraception. 2015;92(3):194–6.CrossRef PubMed
39.Grossman D, Goldstone P. Mifepristone by prescription: a dream in the United States but reality in Australia. Contraception. 2015;92(3):186–9.CrossRef PubMed
40.Raymond EG, Grossman D, Wiebe E, Winikoff B. Reaching women where they are: eliminating the initial in-person medical abortion visit. Contraception. 2015.
41.Grossman DA, Grindlay K, Buchacker T, Potter JE, Schmertmann CP. Changes in service delivery patterns after introduction of telemedicine provision of medical abortion in Iowa. Am J Public Health. 2013;103(1):73–8.PubMedCentral CrossRef PubMed
42.Cameron ST, Glasier A, Dewart H, Johnstone A, Burnside A. Telephone follow-up and self-performed urine pregnancy testing after early medical abortion: a service evaluation. Contraception. 2012;86(1):67–73.CrossRef PubMed
43.Ngoc NT, Bracken H, Blum J, et al. Acceptability and feasibility of phone follow-up after early medical abortion in Vietnam: a randomized controlled trial. Obstet Gynecol. 2014;123(1):88–95.CrossRef PubMed
44.Blum J, Shochet T, Lynd K, et al. Can at-home semi-quantitative pregnancy tests serve as a replacement for clinical follow-up of medical abortion? A US study. Contraception. 2012;86(6):757–62.CrossRef PubMed
45.Bracken H, Lohr PA, Taylor J, Morroni C, Winikoff B. Ru ok? The acceptability and feasibility of remote technologies for follow-up after early medical abortion. Contraception. 2014;90(1):29–35.CrossRef PubMed
46.Grindlay K, Lane K, Grossman D. Women’s and providers’ experiences with medical abortion provided through telemedicine: a qualitative study. Womens Health Issues. 2013;23(2):e117–22.CrossRef PubMed
47.World Health Organization. Safe abortion: technical and policy guidance for health systems. 2nd ed. Geneva: World Health Organization; 2012.
48.Jackson AV, Dayananda I, Fortin JM, Fitzmaurice G, Goldberg AB. Can women accurately assess the outcome of medical abortion based on symptoms alone? Contraception. 2012;85(2):192–7.CrossRef PubMed
49.Cameron ST, Glasier A, Johnstone A, Dewart H, Campbell A. Can women determine the success of early medical termination of pregnancy themselves? Contraception. 2015;91(1):6–11.CrossRef PubMed
50.Michie L, Cameron ST. Simplified follow-up after early medical abortion: 12-month experience of a telephone call and self-performed low-sensitivity urine pregnancy test. Contraception. 2014;89(5):440–5.CrossRef PubMed
51.Lynd K, Blum J, Ngoc NT, Shochet T, Blumenthal PD, Winikoff B. Simplified medical abortion using a semi-quantitative pregnancy test for home-based follow-up. Int J Gynaecol Obstet. 2013;121(2):144–8.CrossRef PubMed
52.Sonalkar S, Hou MY, Borgatta L. Administration of the etonogestrel contraceptive implant on the day of mifepristone for medical abortion: a pilot study. Contraception. 2013;88(5):671–3.CrossRef PubMed
53.Sonalkar S, Mcclusky J, Hou MY, Borgatta L. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study. Contraception. 2015;91(2):174–7.CrossRef PubMed
54.Sneeringer RK, Billings DL, Ganatra B, Baird TL. Roles of pharmacists in expanding access to safe and effective medical abortion in developing countries: a review of the literature. J Public Health Policy. 2012;33(2):218–29.PubMedCentral CrossRef PubMed
55.WHO. Health worker roles in providing safe abortion care and post-abortion contraception. Geneva: World Health Organization. Available from http://​www.​who.​int/​reproductiveheal​th/​publications/​unsafe_​abortion/​abortion-task-shifting/​en/​ . 2015
  • 作者单位：Natalie S. Whaley (1)
    Sarah J. Betstadt (1)

    1. Department of Obstetrics and Gynecology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 668, Rochester, NY, 14642, USA
  • 刊物主题：Obstetrics/Perinatology; Maternal and Child Health; Medicine/Public Health, general; Oncology;
  • 出版者：Springer US
  • ISSN：2161-3303
    • 文摘
    Addressing disparities in abortion access and efforts to end the global problem of unsafe abortion are key public health and human rights priorities. Optimizing the role of various health workers in supporting safe medical abortion practices and working to remove unnecessary barriers to care are key strategies that address inequities in outcomes after abortion worldwide. Medical abortion using evidence-based protocols is effective through 70 days gestation and can safely be provided by non-physician providers in outpatient settings. Removing barriers of in-office administration of mifepristone and simplifying follow-up protocols are evidence-based approaches to expanding access to medical abortion, particularly in settings where access to surgical abortion is limited. Research supports expanding the role of women themselves, as well as task-shifting among health worker teams in providing safe abortion and postabortion care. Simplifying the process of medical abortion, including allowing prescription and home administration of mifepristone and utilizing telemedicine for follow-up protocols are safe and feasible, can optimize use of health resources and improve patient experience with medical abortion.

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700